Although we observed excellent overall long-term breast cancer–specific outcomes, there was an absolute difference of 17.3% between the 10-year BCSS of the subtype with the best prognosis (luminal A-like) and the subtype with the worst prognosis (luminal B-like HER2 positive). This evidence concerns the gene ERBB2 and breast carcinoma.